Madrigal Pharmaceuticals’s $600M offering: The company is raising money to boost the launch of its landmark NASH drug Rezdiffra. It priced 750,000 shares at $260 apiece, with a goal to bring in $600 million. That’s $100 million more than the company initially penciled in when it announced the proposed offering on Monday. Rezdiffra, also known as resmetirom, is the first approved drug for NASH, a liver disease now often referred to as metabolic dysfunction-associated steatohepatitis. — Nicole DeFeudis
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.